Dronedarone (Multaq, X) is an antiarrhythmic agent
that is indicated for patients with atrial fibrillation or atrial flutter.
Lung disease caused by amiodarone, a new antiarrhythmic agent
This is the only antiarrhythmic agent
ever shown to reduce morbidity and mortality in patients with atrial fibrillation or flutter, said Dr.
If an antiarrhythmic agent
is to be given, the route to be used (intravenous or oral)
Amiodarone is widely recognized as the most effective antiarrhythmic agent
at maintaining sinus rhythm in AF patients.
Food & Drug Administration (FDA) has approved the supplemental new drug application for NEXTERONE (amiodarone HCl) Premixed Injection, the first and only premixed intravenous (IV) bag formulation of the antiarrhythmic agent
NYSE: FRX) today announced that its wholly-owned subsidiary Forest Laboratories Holdings Limited and Blue Ash Therapeutics, LLC have entered into an asset purchase agreement, pursuant to which Forest has acquired worldwide rights to azimilide, a novel antiarrhythmic agent
originally developed by Procter & Gamble Pharmaceuticals.
Food and Drug Administration (FDA) approval for multiple presentations of NEXTERONE[R] (amiodarone HCl), an antiarrhythmic agent
The market will also be driven by sales of the antiarrhythmic agent
dronedarone (Sanofi-Aventis's Multaq), which will take share from class IC and class III antiarrhythmics to capture 11 percent of the total atrial fibrillation patient share in 2018.
DALLAS -- The novel investigational antiarrhythmic agent
dronedarone reduced by 27% the 1-year combined incidence of hospitalization or death compared with placebo in a large group of patients with paroxysmal or persistent atrial fibrillation, Dr.
Carrie is uniquely qualified to help drive our success as we approach the launch of our recently approved product NEXTERONE[R] (amiodarone HCl) Premixed Injection, the first and only premixed intravenous (IV) bag formulation of the antiarrhythmic agent
Clinical data and the opinions of interviewed thought leaders indicate that Sanofi-Aventis's Multaq and celivarone, and Aryx Therapeutics' ATI-2042 have advantages in this attribute over propafenone (GlaxoSmithKline/Abbott's Rythmol/Rythmonorm, generics), the sales-leading antiarrhythmic agent
in the market.
SHIELD was a double-blind trial involving 633 patients who received an implantable cardioverter defibrillator (ICD) for secondary prevention of cardiac arrest and were randomized to the novel class III antiarrhythmic agent
, azimilide, at 75 or 125 mg/day or to placebo.